|
The prognostic role of somatic BRCA mutations in ovarian cancer: Preliminary results from an observational multicenter cohort study. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; MSD; PharmaMar; Tesaro |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Pfizer |
Consulting or Advisory Role - Amgen; MSD; Novartis; Pfizer |
Speakers' Bureau - AstraZeneca; MSD Oncology |